Your browser is no longer supported. Please, upgrade your browser.
Settings
EYPT [NASD]
EyePoint Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.90 Insider Own11.00% Shs Outstand24.73M Perf Week0.93%
Market Cap280.23M Forward P/E- EPS next Y-1.45 Insider Trans0.00% Shs Float19.89M Perf Month11.85%
Income-44.50M PEG- EPS next Q-0.43 Inst Own68.90% Short Float6.38% Perf Quarter-18.52%
Sales34.30M P/S8.17 EPS this Y35.00% Inst Trans155.00% Short Ratio6.89 Perf Half Y114.57%
Book/sh4.68 P/B2.08 EPS next Y16.20% ROA-41.80% Target Price- Perf Year17.99%
Cash/sh4.81 P/C2.02 EPS next 5Y- ROE-121.90% 52W Range3.51 - 15.06 Perf YTD47.72%
Dividend- P/FCF- EPS past 5Y12.30% ROI- 52W High-35.46% Beta1.33
Dividend %- Quick Ratio11.40 Sales past 5Y84.30% Gross Margin81.80% 52W Low176.84% ATR0.50
Employees101 Current Ratio11.90 Sales Q/Q-2.70% Oper. Margin- RSI (14)54.08 Volatility4.74% 5.34%
OptionableYes Debt/Eq0.33 EPS Q/Q56.50% Profit Margin- Rel Volume0.64 Prev Close9.51
ShortableYes LT Debt/Eq0.33 EarningsMay 05 BMO Payout- Avg Volume184.07K Price9.72
Recom2.00 SMA203.70% SMA501.30% SMA20020.73% Volume117,926 Change2.21%
Mar-01-21Initiated Cowen Outperform $25
Jan-28-21Initiated Cantor Fitzgerald Overweight $22
Apr-06-20Downgrade B. Riley FBR Buy → Neutral $4 → $1
Nov-04-19Resumed Laidlaw Buy $5
Sep-12-19Initiated Guggenheim Buy
May-26-21 07:00AM  
May-25-21 07:00AM  
May-05-21 08:45AM  
07:00AM  
06:45AM  
Apr-28-21 12:33PM  
07:00AM  
Mar-04-21 08:15AM  
07:00AM  
06:30AM  
Feb-25-21 04:00PM  
07:00AM  
Feb-04-21 12:29PM  
Feb-01-21 10:17PM  
04:01PM  
Jan-28-21 07:00AM  
Jan-11-21 04:01PM  
Jan-05-21 01:36PM  
01:37AM  
Jan-03-21 07:00PM  
Dec-18-20 07:00AM  
Dec-08-20 09:20AM  
Dec-03-20 07:00AM  
Nov-25-20 09:13AM  
Nov-19-20 07:00AM  
Nov-16-20 07:00AM  
Nov-10-20 07:00AM  
Nov-05-20 09:15AM  
07:00AM  
Oct-29-20 12:35PM  
07:00AM  
Oct-08-20 07:00AM  
Oct-07-20 07:00AM  
Sep-30-20 08:25AM  
Sep-10-20 07:00AM  
Aug-26-20 11:51AM  
Aug-24-20 07:00AM  
Aug-20-20 07:00AM  
Aug-05-20 09:25AM  
08:19AM  
07:00AM  
Aug-04-20 07:00AM  
Jul-29-20 07:00AM  
Jul-27-20 07:00AM  
Jul-13-20 07:00AM  
Jul-02-20 07:59AM  
Jun-24-20 01:01PM  
Jun-18-20 08:42AM  
May-27-20 12:50PM  
May-26-20 07:00AM  
May-18-20 07:00AM  
May-06-20 08:45AM  
08:21AM  
07:00AM  
Apr-29-20 08:00AM  
Apr-08-20 06:10AM  
Apr-01-20 11:35AM  
Mar-31-20 10:54AM  
Mar-23-20 11:39PM  
Mar-05-20 08:25AM  
07:00AM  
Mar-02-20 07:00AM  
Feb-27-20 07:00AM  
Feb-21-20 09:09AM  
07:46AM  
Feb-20-20 04:01PM  
Feb-18-20 07:00AM  
Feb-04-20 07:51AM  
Feb-03-20 05:24PM  
Jan-30-20 07:56AM  
Jan-27-20 07:00AM  
Jan-23-20 07:00AM  
Dec-22-19 05:31PM  
Dec-04-19 07:00AM  
Nov-25-19 06:46PM  
Nov-19-19 10:54AM  
Nov-14-19 07:00AM  
Nov-07-19 07:30AM  
06:00AM  
Nov-04-19 07:00AM  
Nov-01-19 07:00AM  
Oct-31-19 10:35AM  
Oct-24-19 07:00AM  
Oct-02-19 04:05PM  
Sep-27-19 07:00AM  
Sep-26-19 07:00AM  
Sep-09-19 07:00AM  
Sep-06-19 08:32AM  
Aug-23-19 11:24AM  
Aug-07-19 07:35AM  
06:00AM  
Jul-31-19 10:36AM  
07:06AM  
Jul-30-19 04:15PM  
Jul-25-19 07:00AM  
Jul-24-19 07:00AM  
Jul-23-19 07:00AM  
Jul-15-19 07:00AM  
Jul-08-19 09:13AM  
Jul-01-19 07:00AM  
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lurker NancyPresident & CEOJun 14Option Exercise0.004,5000113,546Jun 15 05:04 PM
Paggiarino Dario A.Chief Medical OfficerJun 14Option Exercise0.001,420013,012Jun 15 05:04 PM
Paggiarino Dario A.Chief Medical OfficerFeb 28Option Exercise0.004,105013,015Mar 02 07:26 PM
ANDO GORANDirectorFeb 28Option Exercise0.002,15002,150Mar 02 07:24 PM
Jones David ScottSVP & Chief Commercial OfficerFeb 28Option Exercise0.004,10509,082Mar 02 07:25 PM
Godshall Douglas EvanDirectorFeb 28Option Exercise0.001,90005,516Mar 02 07:22 PM
DICICCO WENDY FDirectorFeb 28Option Exercise0.001,90001,900Mar 02 07:22 PM
Landis John B.DirectorFeb 28Option Exercise0.001,90005,900Mar 02 07:21 PM
GUYER DAVID RDirectorFeb 28Option Exercise0.001,90001,900Mar 02 07:22 PM
Lurker NancyPresident & CEOFeb 28Option Exercise0.0012,4670109,046Mar 02 07:21 PM
Lurker NancyPresident & CEOFeb 21Option Exercise0.0013,717096,579Feb 23 09:01 PM
Elston GeorgeChief Financial OfficerSep 04Buy0.4810,0004,80040,000Sep 09 09:16 AM
Elston GeorgeChief Financial OfficerAug 24Buy0.6110,0006,11230,000Aug 26 09:21 AM
Jones David ScottSVP & Chief Commercial OfficerJun 30Option Exercise0.0041,050041,050Jul 02 06:15 PM
Paggiarino Dario A.Chief Medical OfficerJun 30Option Exercise0.0041,0500101,193Jul 02 06:14 PM
Lurker NancyPresident & CEOJun 30Option Exercise0.00124,6670784,467Jul 02 06:13 PM
Lurker NancyPresident & CEOJun 27Option Exercise0.0040,0000659,800Jun 30 07:40 PM
Paggiarino Dario A.Chief Medical OfficerJun 27Option Exercise0.0010,000063,079Jun 30 07:52 PM